menu
    • menu
    [{"orgOrder":0,"company":"Center for International Blood and Marrow Transplant Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase IV","graph3":"Center for International Blood and Marrow Transplant Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Center for International Blood and Marrow Transplant Research \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Center for International Blood and Marrow Transplant Research \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Dotatate Lutenium Lu-177","moa":"","graph1":"Oncology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"","graph1":"Oncology","graph2":"Phase IV","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Salix Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            UroGen Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            UroGen Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mitomycin

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            JELMYTO® Real-World Study Matches OLYMPUS in Cancer Response Rates

                            Details : Jelmyto® (mitomycin) is a FDA approved pyelocalyceal solution is a mitomycin-containing reverse thermal gel indicated for primary chemoablative treatment of LG-UTUC in adults.

                            Brand Name : Jelmyto

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 04, 2024

                            Lead Product(s) : Mitomycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Salix Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Salix Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naltrexone Methobromide

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Salix Announces Phase 2 Study of RELISTOR® in Resectable HNSCC

                            Details : Relistor (methylnaltrexone bromide) is an opioid antagonist, its subcutaneous formulation is being investigated in patients with resectable head and neck squamous cell carcinoma.

                            Brand Name : Relistor

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 06, 2024

                            Lead Product(s) : Naltrexone Methobromide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nadofaragene Firadenovec-vncg

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase 4 Study Evaluates ADSTILADRIN® Use in Real-World Setting

                            Details : Adstiladrin (nadofaragene firadenovec-vncg) is an FDA-approved gene therapy delivering a human IFNα2b gene to the bladder for treating BCG-unresponsive non-muscle invasive bladder cancer.

                            Brand Name : Adstiladrin

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 24, 2024

                            Lead Product(s) : Nadofaragene Firadenovec-vncg

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotatate Lutenium Lu-177

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novartis Radioligand Therapy Lutathera® Demonstrated Statistically Significant and Clinically Meaningful Prog...

                            Details : Lutathera (lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) is an Advanced Accelerator Applications RLT approved in the United States for the treatment of SSTR-positive GEP-NETs.

                            Brand Name : Lutathera

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 25, 2023

                            Lead Product(s) : Dotatate Lutenium Lu-177

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Legend Biotech

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Legend Biotech

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciltacabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : $650.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen

                            Details : Legend Biotech entered into the agreement with Janssen to develop, manufacture and commercialize cilta-cel for the treatment of multiple myeloma. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy.

                            Brand Name : Cilta-cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $350.0 million

                            February 11, 2022

                            Lead Product(s) : Ciltacabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : $650.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bayer AG

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darolutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Pr...

                            Details : NUBEQA significantly reduced the risk of death by 31%, offering men with non-metastatic castration-resistant prostate cancer (nmCRPC) extended survival for a greater chance of living longer.

                            Brand Name : Nubeqa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 08, 2021

                            Lead Product(s) : Darolutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bristol Myers Squibb

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb Statement on Opdivo (Nivolumab) Small Cell Lung Cancer U.S. Indication

                            Details : The trial demonstrated encouraging response rates and duration of response with Opdivo in SCLC, an aggressive and difficult-to-treat cancer.

                            Brand Name : Opdivo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 29, 2020

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Center for International Blood and Marrow Transplant Research

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Center for International Blood and Marrow Transplant Research

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CIBMTR Completes Enrollment in Yescarta® Long-Term Post-Marketing Safety Study

                            Details : Yescarta is the first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

                            Brand Name : Yescarta

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 08, 2020

                            Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Takeda Pharmaceutical

                            Japan arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO in Multiple Myeloma as a First-Line ...

                            Details : Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation.

                            Brand Name : Ninlaro

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 12, 2020

                            Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth